SLC5A2 and type 2 diabetes mellitus: In type 2 diabetic patients at high risk of experiencing cardiovascular events, treatment with sodium–glucose cotransporter 2 (SGLT2) inhibitors, a new class of glucose-lowering agent, led to a lower rate of death from all cardiovascular causes in the EMPA-REG OUTCOMES trial (Zinman et al., 2015).